Title:
ANTI-C2 ANTIBODIES AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/143583
Kind Code:
A1
Abstract:
Provided is inhibition of the complement signaling using an anti-C2 antibody or a fragment thereof. Specifically, provided are methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with the anti-C2 antibody or a fragment thereof.
Inventors:
TSUI PING (US)
JIANG BINGBING (CN)
ZHANG JIANJUN (CN)
XU YINGYING (CN)
HU XIAOXIA (CN)
FEI DONGQIONG (CN)
SONG WENCHAO (US)
MIWA TAKASHI (US)
GULLIPALLI DAMODAR (US)
SATO SAYAKA (US)
JIANG BINGBING (CN)
ZHANG JIANJUN (CN)
XU YINGYING (CN)
HU XIAOXIA (CN)
FEI DONGQIONG (CN)
SONG WENCHAO (US)
MIWA TAKASHI (US)
GULLIPALLI DAMODAR (US)
SATO SAYAKA (US)
Application Number:
PCT/CN2023/073730
Publication Date:
August 03, 2023
Filing Date:
January 29, 2023
Export Citation:
Assignee:
KIRA PHARMACEUTICALS SUZHOU LTD (CN)
UNIV PENNSYLVANIA (US)
UNIV PENNSYLVANIA (US)
International Classes:
C07K16/18; A61K39/395; A61P7/00; C12N5/16; C12P21/08
Domestic Patent References:
| WO2021026609A1 | 2021-02-18 | |||
| WO2001070818A1 | 2001-09-27 | |||
| WO2014189378A1 | 2014-11-27 | |||
| WO2001051512A2 | 2001-07-19 | |||
| WO2017136355A1 | 2017-08-10 |
Other References:
KRISHNAN, V. ET AL.: "The Crystal Structure of C2a, the Catalytic Fragment of Classical Pathway C3- and C5-convertase of Human Complement", J MOL BIOL, vol. 367, no. 1, 16 March 2007 (2007-03-16), pages 224 - 233, XP005894346, DOI: 10.1016/j.jmb.2006.12.039
Attorney, Agent or Firm:
KANGXIN PARTNERS , P.C. (CN)
Download PDF:
Previous Patent: TARGETED PHOTODYNAMIC THERAPY FOR DISEASE ASSOCIATED WITH SARS-COV-2
Next Patent: METHOD, APPARATUS, AND MEDIUM FOR VIDEO PROCESSING
Next Patent: METHOD, APPARATUS, AND MEDIUM FOR VIDEO PROCESSING